Navigation Links
REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
Date:1/17/2012

and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or CHMP's 120-day questions, the FDA's requests stemming from the end-of-review meeting or the results of the FORTRESS study and subsequent meetings and communications will be sufficient to satisfy the FDA or CHMP's safety concerns, that the FDA or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful.  VIVUS does not undertake an obligation to update or revise any forward-looking statements.  Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2
'/>"/>
SOURCE VIVUS
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
2. Secret of sandcastle construction could help revive ancient building technique, researchers say
3. Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures
4. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
5. NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
8. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
11. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
(Date:10/19/2014)... report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla Market ... (2011 - 2016)," analyzes the chocolate market by ... market drivers, restraints, and opportunities for the chocolate market ... chocolate market is expected to grow from $83.2 billion ... CAGR of 2.7% from 2011 to 2016. , Get ...
(Date:10/18/2014)... The “Human Insulin Market- by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/18/2014)... Asia-Pacific hardware encryption display market report defines and segments ... of revenue. This market was valued $5,154.0 million in ... 2018, at a CAGR of 58.4% from 2013 to ... hardware encryption market report, to get an idea of ... of the segmentation of the market, and is supported ...
Breaking Biology Technology:The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... WEST CONSHOHOCKEN, Pa., Nov. 12 GEL Interactive,Technologies, ... Kent,Senior Product Director, will be a featured speaker ... Annual Forum on Defining Appropriate,and Effective Interactions with ... 5th Annual Forum provides a platform for attendees ...
... MELBOURNE, Australia, Nov. 12 Phosphagenics,Limited ("Phosphagenics") (ASX: ... initiated a phase 1 human clinical trial ... the targeted delivery of a leading non ... compare the,bioavailability and penetration of the topically ...
... EMERYVILLE, Calif., Nov. 12 Bionovo, Inc.,(Nasdaq: BNVI ... to the,company,s Scientific Advisory Board. Dr. Weiss is a ... a leading researcher,at the Cardiovascular Research Institute and the ... (UCSF)., "We are very excited to have Ethan ...
Cached Biology Technology:Cadient Group's GEL Interactive Technologies to Present and Exhibit at CBI's 5th Annual Forum 2Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 3
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... a share of grants totalling over 1m to target ... Dr. Declan Bates, a senior lecturer in the Department ... of 1,068,000 in the form of just two research ... Council (EPSRC) and the other from the Biotechnology and ...
... molecular mechanisms by which plants protect themselves from oxidation ... a team of researchers has discovered a molecular dimmer ... moving through the system of light harvesting proteins. This ... artificial photosynthesis systems that could provide the world with ...
... Fla. Two University of Miami (UM) students have ... Foundation (NSF) for their doctoral work on coral reefs. ... years of support for their work in the laboratory ... Division of Marine Biology and Fisheries at UMs Rosenstiel ...
Cached Biology News:Engineer to spearhead research into cell metabolism and medical injuries 2Berkeley researchers identify photosynthetic dimmer switch 2Berkeley researchers identify photosynthetic dimmer switch 3Berkeley researchers identify photosynthetic dimmer switch 4Everything's coming up corals 2Everything's coming up corals 3
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... incubation trays are disposable trays ... antigens that have been blotted ... has eight 10.5 cm x ... strips cut from blotted membrane ...
... in permanent mounting media. It is ... immunohistochemical organic insoluble substrates such as ... and any other organic solvent compatible ... can be used for histology and ...
... The Gene Inspector can perform many sophisticated DNA ... is much more than just another sequence analysis ... entire suite of analyses to be performed each ... design custom style sheets which specify exactly how ...
Biology Products: